+Compare
TCRX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
247.73M

TCRX TScan Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for TCRX with price predictions
07:00 PM EST Nov 27, 2023

TCRX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TCRX turned positive on November 22, 2023. Looking at past instances where TCRX's MACD turned positive, the stock continued to rise in of 23 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2023. You may want to consider a long position or call options on TCRX as a result. In of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in of 109 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 75 cases where TCRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TCRX moved out of overbought territory on November 20, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TCRX broke above its upper Bollinger Band on November 17, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.483) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (14.793) is also within normal values, averaging (329.780).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 467.58B. NVO holds the highest valuation in this group at 467.58B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 33%, and the average quarterly price growth was 8%. SEPSF experienced the highest price growth at 145%, while THAR experienced the biggest fall at -73%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -50%. For the same stocks of the Industry, the average monthly volume growth was -53% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

TCRX is expected to report earnings to rise 23.33% to -29 cents per share on March 06

TScan Therapeutics TCRX Stock Earnings Reports
Q4'23
Est.
$-0.30
Q3'23
Beat
by $0.21
Q2'23
Beat
by $0.25
Q1'23
Missed
by $0.24
Q4'22
Missed
by $0.06
The last earnings report on November 09 showed earnings per share of -23 cents, beating the estimate of -45 cents. With 38.33K shares outstanding, the current market capitalization sits at 247.73M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
138
Web
https://www.tscan.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWMCX41.41N/A
N/A
Hotchkis & Wiley Mid-Cap Value C
MGBRX16.25N/A
N/A
MFS Global Total Return R2
ATHDX23.47N/A
N/A
American Century Heritage R6
VSQAX15.79N/A
N/A
Invesco MSCI World SRI Index A
SPRNX73.38N/A
N/A
Sprucegrove International Eq Inst

TCRX and

Correlation & Price change

A.I.dvisor tells us that TCRX and DRTS have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TCRX and DRTS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+1.17%
DRTS - TCRX
23%
Poorly correlated
+0.66%
HOOK - TCRX
23%
Poorly correlated
+2.11%
TNYA - TCRX
22%
Poorly correlated
+3.26%
VYNE - TCRX
22%
Poorly correlated
-1.00%
IMAB - TCRX
22%
Poorly correlated
-4.38%
More